Potential probe for isolation of the β-adrenoceptor, chloropractolol

Mordechai Erez*, Marta Weinstock, Sasson Cohen, Gad Shtacher

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


A TECHNIQUE which has proved highly successful in the isolation and identification of pharmacological receptors, is the use of a high affinity, selective label which binds irreversibly to the receptor1. We report here our findings with a new irreversible, potent and cardioselective (β-1) β adrenoceptor antagonist, chloropractolol (I). This new compound is a modification (Fig. 1) of practolol (II), and represents the first known selective, irreversible β antagonist. Chloropractolol (I) was prepared with the intention of incorporating an alkylating function into the parent compound, while maintaining β-1 selectivity. An additional advantage of using practolol (II) rather than propranolol as the parent molecule, is that the resultant compound should, like practolol, lack nonspecific membrane stabilising effect2 and any interaction with 5-hydroxytryptamine receptors 3.

Original languageEnglish
Pages (from-to)635-636
Number of pages2
Issue number5510
StatePublished - 1975


Dive into the research topics of 'Potential probe for isolation of the β-adrenoceptor, chloropractolol'. Together they form a unique fingerprint.

Cite this